Russell Investments Group Ltd. Acquires 4,898 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Russell Investments Group Ltd. increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 174,286 shares of the biopharmaceutical company’s stock after purchasing an additional 4,898 shares during the period. Russell Investments Group Ltd.’s holdings in Xenon Pharmaceuticals were worth $8,028,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its position in Xenon Pharmaceuticals by 98.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,651 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 818 shares during the last quarter. Assetmark Inc. raised its position in Xenon Pharmaceuticals by 21.5% in the 3rd quarter. Assetmark Inc. now owns 7,103 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 1,258 shares during the period. Moody Aldrich Partners LLC bought a new stake in Xenon Pharmaceuticals in the third quarter worth about $312,000. Barclays PLC grew its stake in shares of Xenon Pharmaceuticals by 3.7% during the third quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 342 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in Xenon Pharmaceuticals by 25.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 10,188 shares of the biopharmaceutical company’s stock valued at $348,000 after acquiring an additional 2,096 shares during the period. Institutional investors own 95.45% of the company’s stock.

Analysts Set New Price Targets

XENE has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $62.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, April 12th. Wedbush raised their target price on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, April 10th. Finally, Royal Bank of Canada decreased their price objective on Xenon Pharmaceuticals from $56.00 to $55.00 and set an “outperform” rating for the company in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.44.

Xenon Pharmaceuticals Trading Up 0.6 %

NASDAQ XENE opened at $43.43 on Wednesday. Xenon Pharmaceuticals Inc. has a 12-month low of $27.99 and a 12-month high of $50.99. The firm’s fifty day simple moving average is $43.06 and its two-hundred day simple moving average is $41.50. The firm has a market capitalization of $3.28 billion, a P/E ratio of -15.97 and a beta of 1.19.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.12. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business earned ($0.57) EPS. As a group, sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -3.04 earnings per share for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $601,640.00. Following the sale, the director now owns 2,000 shares of the company’s stock, valued at approximately $92,560. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $601,640.00. Following the completion of the sale, the director now owns 2,000 shares of the company’s stock, valued at approximately $92,560. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sherrington Robin sold 7,137 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the completion of the transaction, the executive vice president now directly owns 8,398 shares in the company, valued at $388,659.44. The disclosure for this sale can be found here. 5.43% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.